PBLA Stock Overview
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Panbela Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.41 |
| 52 Week High | US$300.00 |
| 52 Week Low | US$0.35 |
| Beta | 0.78 |
| 1 Month Change | -24.82% |
| 3 Month Change | -64.64% |
| 1 Year Change | -99.84% |
| 3 Year Change | -100.00% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Panbela Therapeutics dips 24% on pricing $6M public offering
Sep 30Panbela Therapeutics GAAP EPS of -$1.51
Aug 15Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Feb 18
Panbela: Biotech With Updated Patent Protection And Unmet Market Target Indication
Jan 06Will Panbela Therapeutics (NASDAQ:PBLA) Spend Its Cash Wisely?
Nov 02Companies Like Panbela Therapeutics (NASDAQ:PBLA) Are In A Position To Invest In Growth
Jul 15Panbela Therapeutics to join Russell Microcap Index
Jun 09We Think Panbela Therapeutics (NASDAQ:PBLA) Can Afford To Drive Business Growth
Mar 29Shareholder Returns
| PBLA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.05% | 4.8% | 0.7% |
| 1Y | -99.8% | 2.8% | 23.9% |
Return vs Industry: PBLA underperformed the US Biotechs industry which returned 2.7% over the past year.
Return vs Market: PBLA underperformed the US Market which returned 23.9% over the past year.
Price Volatility
| PBLA volatility | |
|---|---|
| PBLA Average Weekly Movement | 21.5% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PBLA's share price has been volatile over the past 3 months.
Volatility Over Time: PBLA's weekly volatility has decreased from 30% to 22% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2011 | 8 | Jennifer Simpson | www.panbela.com |
Panbela Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The company’s lead product candidates are Ivospemin (SBP-101), a proprietary polyamine analogue, which has completed Phase Ia/Ib clinical trial for the treatment of patients with metastatic pancreatic ductal adenocarcinoma; Flynpovi, a combination of eflornithine (CPP-1X) and sulindac which is in Phase III clinical trials; and Eflornithine, an enzyme-activated irreversible inhibitor of the enzyme ornithine decarboxylase, currently under Phase I/II trial. It has a research agreement with the Johns Hopkins University School of Medicine for the development of ivospemin.
Panbela Therapeutics, Inc. Fundamentals Summary
| PBLA fundamental statistics | |
|---|---|
| Market cap | US$1.99m |
| Earnings (TTM) | -US$34.40m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.1x
P/E RatioIs PBLA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBLA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$34.40m |
| Earnings | -US$34.40m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -7.09 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -110.3% |
How did PBLA perform over the long term?
See historical performance and comparison